Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

The Association between Prolonged Jaundice and UGT1A1 Gene Polymorphism (G71R) in Gilbert's Syndrome.

Alaee E, Bazrafshan B, Azaminejad AR, Fouladinejad M, Shahbazi M.

J Clin Diagn Res. 2016 Nov;10(11):GC05-GC08. doi: 10.7860/JCDR/2016/19004.8810.

2.

The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids.

Cassidy A, Minihane AM.

Am J Clin Nutr. 2017 Jan;105(1):10-22. doi: 10.3945/ajcn.116.136051. Review.

3.

Features of an altered AMPK metabolic pathway in Gilbert's Syndrome, and its role in metabolic health.

Mölzer C, Wallner M, Kern C, Tosevska A, Schwarz U, Zadnikar R, Doberer D, Marculescu R, Wagner KH.

Sci Rep. 2016 Jul 21;6:30051. doi: 10.1038/srep30051.

4.

Thyrotoxic crisis presenting with jaundice.

Wickramasinghe RD, Luke WA, Sebastiampillai BS, Gunathilake MP, Premaratna R.

BMC Res Notes. 2016 Jun 23;9:320. doi: 10.1186/s13104-016-2126-z.

5.

Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.

Yu QQ, Qiu H, Zhang MS, Hu GY, Liu B, Huang L, Liao X, Li QX, Li ZH, Yuan XL.

World J Gastroenterol. 2016 Apr 28;22(16):4250-8. doi: 10.3748/wjg.v22.i16.4250.

6.

Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry.

Brureau L, Moningo D, Emeville E, Ferdinand S, Punga A, Lufuma S, Blanchet P, Romana M, Multigner L.

PLoS One. 2016 Apr 13;11(4):e0153609. doi: 10.1371/journal.pone.0153609.

8.

Longer telomeres in chronic, moderate, unconjugated hyperbilirubinaemia: insights from a human study on Gilbert's Syndrome.

Tosevska A, Moelzer C, Wallner M, Janosec M, Schwarz U, Kern C, Marculescu R, Doberer D, Weckwerth W, Wagner KH.

Sci Rep. 2016 Mar 1;6:22300. doi: 10.1038/srep22300.

10.

UGT genotyping in belinostat dosing.

Goey AK, Figg WD.

Pharmacol Res. 2016 Mar;105:22-7. doi: 10.1016/j.phrs.2016.01.002. Review.

PMID:
26773202
11.

Association between UGT1A1 Polymorphism and Risk of Laryngeal Squamous Cell Carcinoma.

Huangfu H, Pan H, Wang B, Wen S, Han R, Li L.

Int J Environ Res Public Health. 2016 Jan 7;13(1). pii: E112. doi: 10.3390/ijerph13010112.

12.

Identification of Promotor and Exonic Variations, and Functional Characterization of a Splice Site Mutation in Indian Patients with Unconjugated Hyperbilirubinemia.

Gupta N, Benjamin M, Kar A, Munjal SD, Sarangi AN, Dalal A, Aggarwal R.

PLoS One. 2015 Dec 30;10(12):e0145967. doi: 10.1371/journal.pone.0145967.

13.

Serum bilirubin concentration is modified by UGT1A1 haplotypes and influences risk of type-2 diabetes in the Norfolk Island genetic isolate.

Benton MC, Lea RA, Macartney-Coxson D, Bellis C, Carless MA, Curran JE, Hanna M, Eccles D, Chambers GK, Blangero J, Griffiths LR.

BMC Genet. 2015 Dec 2;16:136. doi: 10.1186/s12863-015-0291-z.

14.

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

Fujita K, Kubota Y, Ishida H, Sasaki Y.

World J Gastroenterol. 2015 Nov 21;21(43):12234-48. doi: 10.3748/wjg.v21.i43.12234. Review.

15.

Inherited disorders of bilirubin clearance.

Memon N, Weinberger BI, Hegyi T, Aleksunes LM.

Pediatr Res. 2016 Mar;79(3):378-86. doi: 10.1038/pr.2015.247. Review.

16.

How to Use SNP_TATA_Comparator to Find a Significant Change in Gene Expression Caused by the Regulatory SNP of This Gene's Promoter via a Change in Affinity of the TATA-Binding Protein for This Promoter.

Ponomarenko M, Rasskazov D, Arkova O, Ponomarenko P, Suslov V, Savinkova L, Kolchanov N.

Biomed Res Int. 2015;2015:359835. doi: 10.1155/2015/359835.

17.
18.

Pharmacogenomics in the clinic.

Relling MV, Evans WE.

Nature. 2015 Oct 15;526(7573):343-50. doi: 10.1038/nature15817. Review.

19.

Association of Neonatal Hyperbilirubinemia with UGT1A1 Gene Polymorphisms: A Meta-Analysis.

Yu Z, Zhu K, Wang L, Liu Y, Sun J.

Med Sci Monit. 2015 Oct 15;21:3104-14.

20.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW; Clinical Pharmacogenetics Implementation Consortium..

Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Review.

Items per page

Supplemental Content

Support Center